( Amex: RNN ) Rexahn with a nice Robust Drug Pipeline that Teva and Pfizer like so much. Rexahn right now can be bought for pennies on the dollar. Yes indeed, Zoraxel is the drug I am waiting for because they say it will be better than viagra and all the rest of the ED drugs on the market today. Don't Worry Pfizer or other will buy this Penny Biotech for mucho Bucks Soon.
Zoraxel is still far away and will not be able to compete the ED battle.
Abbott will start marketing by mid-2012 the ED treatment VITAROS in Canada from Apricus Bio (APRI). VITAROS will replace the PDE5 drugs (Viagra, Cialis, Levitra, etc.) as the ED product of choice since it only takes effect in 5 minutes and has no side-effects like the PDE5 drugs (loss vision, heart problem, etc.).
VITAROS will be marketed in Germany by Sandoz (a division of Novartis), in Italy by Bracco, in the Middle East/Israel by Elis Pharm. and Neopharm, , and in the US by Warner Chilcott. More partners will be forthcoming for Asia, South America, and the rest of the world.
Buy APRI before it rockets. It has very robust pipeline. Other products are FEMPROX, the leading female sexual arousal disorder treatment, MYCOVA, PreVonco, and a host of oncology treatment. All of their products work on their proprietary proven NexACT drug delivery system technology.
Specifically, we see two “developments” in 2012 that could generate revenues of $20-$25 million for RNN. This first is a milestone payment of $3-5 million from Teva, when RNN begins Phase I clinical trials for RX-3117 (probably in the first quarter of 2012).